The International Society for Vaccines is an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines - 2017 ISV Annual Congress

Paper of the Month April 2013

Boost Interval Matters: A Randomized Phase I Study to Identify the Minimum Interval to Observe the H5DNA Influenza Vaccine Priming Effect.

J Infect Dis. 2013 Apr 30. [Epub ahead of print].

Authors

Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS; the VRC 310 Study Team.

Abstract

Background:

H5DNA priming was previously shown to improve antibody response to H5N1 monovalent inactivated vaccine (MIV) with a 24-week interval. This study defines the shortest prime-boost interval with improved response.

Methods:

We administered H5DNA followed 4, 8, 12, 16, or 24 weeks by MIV as compared to two doses of MIV (24-week).

Results:

H5DNA priming with ≥12 week MIV boost showed improved response, with positive HAI in 91% [geometric mean titer (GMT) 141-206]; compared to ≤8-week boost (55-70%; GMT 51-70) or MIV-MIV 24-week boost (44% ; GMT 27).

Conclusions:

H5DNA priming enhances antibody responses after an MIV boost when the interval is 12-24 weeks